Join
Live feed
·
NEWSReleasevia Quantisnow
CASI Pharmaceuticals Inc. logo

CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

ByQuantisnow·Wall Street's wire, on your screen.
CASI· CASI Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CASI (CASI Pharmaceuticals Inc.) and more on Quantisnow.